Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00972G1085
Share Class Description:
AKTX: ADRDescription
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.05 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.9 | |||||
| 3-Year EPS without NRI Growth Rate | 45 | |||||
| 3-Year FCF Growth Rate | 32.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.37 | |||||
| 9-Day RSI | 32.19 | |||||
| 14-Day RSI | 29.07 | |||||
| 6-1 Month Momentum % | -42.03 | |||||
| 12-1 Month Momentum % | -54.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.95 | |||||
| Quick Ratio | 0.95 | |||||
| Cash Ratio | 0.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| EV-to-EBIT | -0.34 | |||||
| EV-to-EBITDA | -0.34 | |||||
| EV-to-FCF | -0.35 | |||||
| Earnings Yield (Greenblatt) % | -294.12 | |||||
| FCF Yield % | -174.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akari Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0.64 | ||
| Volatility % | 75.9 | ||
| 14-Day RSI | 29.07 | ||
| 14-Day ATR ($) | 0.157841 | ||
| 20-Day SMA ($) | 1.47908 | ||
| 12-1 Month Momentum % | -54.55 | ||
| 52-Week Range ($) | 1.0775 - 5.5 | ||
| Shares Outstanding (Mil) | 7.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akari Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(AKTX)'s stock price today?
The current price of AKTX is $1.19. The 52 week high of AKTX is $5.50 and 52 week low is $1.08.
When is next earnings date of Akari Therapeutics PLC(AKTX)?
The next earnings date of Akari Therapeutics PLC(AKTX) is 2024-05-01 Est..
Does Akari Therapeutics PLC(AKTX) pay dividends? If so, how much?
Akari Therapeutics PLC(AKTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers